Combined BRAF and MEK inhibitors, as compared with BRAF inhibition alone, provided remarkable response rates in melanoma, delayed the emergence of resistance, and reduced toxic effects in patients with BRAFV600E-mutated melanoma (91, 92). The gene discussed is MAP2K7; the disease is melanoma.